Connection

Michael Zile to Hospitalization

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Hospitalization.
Michael Zile
Connection Strength
2.937
Hospitalization
  1. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. Clin Cardiol. 2020 Dec; 43(12):1501-1510.
    View in: PubMed
    Score: 0.464
  2. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 09 11; 398(10304):991-1001.
    View in: PubMed
    Score: 0.124
  3. Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance. ESC Heart Fail. 2020 10; 7(5):3040-3048.
    View in: PubMed
    Score: 0.115
  4. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
    View in: PubMed
    Score: 0.108
  5. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
    View in: PubMed
    Score: 0.106
  6. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.
    View in: PubMed
    Score: 0.105
  7. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients?With HFrEF. J Am Coll Cardiol. 2019 02 26; 73(7):795-806.
    View in: PubMed
    Score: 0.104
  8. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
    View in: PubMed
    Score: 0.103
  9. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.095
  10. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Nov; 9(11).
    View in: PubMed
    Score: 0.089
  11. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):478-486.
    View in: PubMed
    Score: 0.080
  12. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC Heart Fail. 2015 Jun; 3(6):429-441.
    View in: PubMed
    Score: 0.080
  13. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail. 2015 Feb; 17(2):169-76.
    View in: PubMed
    Score: 0.078
  14. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). Circ Heart Fail. 2015 Jan; 8(1):17-24.
    View in: PubMed
    Score: 0.078
  15. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014 Jul; 16(7):778-87.
    View in: PubMed
    Score: 0.075
  16. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011 Sep; 4(5):561-8.
    View in: PubMed
    Score: 0.061
  17. Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol. 2007 Feb 15; 99(4):460-4.
    View in: PubMed
    Score: 0.045
  18. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J Am Heart Assoc. 2021 12 07; 10(23):e021494.
    View in: PubMed
    Score: 0.031
  19. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. J Card Fail. 2021 09; 27(9):1027-1030.
    View in: PubMed
    Score: 0.031
  20. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Circ Heart Fail. 2021 04; 14(4):e007901.
    View in: PubMed
    Score: 0.030
  21. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.030
  22. Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. Am J Med. 2021 06; 134(6):797-804.
    View in: PubMed
    Score: 0.030
  23. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. JAMA. 2020 10 20; 324(15):1522-1531.
    View in: PubMed
    Score: 0.029
  24. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 12; 22(12):2370-2379.
    View in: PubMed
    Score: 0.029
  25. The prevalence and importance of frailty in heart failure with reduced ejection fraction?-?an analysis of PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 11; 22(11):2123-2133.
    View in: PubMed
    Score: 0.028
  26. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.
    View in: PubMed
    Score: 0.028
  27. Covariate adjusted reanalysis of the I-Preserve trial. Clin Res Cardiol. 2020 Nov; 109(11):1358-1365.
    View in: PubMed
    Score: 0.028
  28. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.028
  29. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 03; 22(3):528-538.
    View in: PubMed
    Score: 0.028
  30. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
    View in: PubMed
    Score: 0.028
  31. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
    View in: PubMed
    Score: 0.027
  32. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 08; 21(8):974-984.
    View in: PubMed
    Score: 0.027
  33. Differential Impact of Heart Failure With?Reduced Ejection Fraction on?Men?and?Women. J Am Coll Cardiol. 2019 01 08; 73(1):29-40.
    View in: PubMed
    Score: 0.026
  34. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018 12 11; 138(24):2763-2773.
    View in: PubMed
    Score: 0.026
  35. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.026
  36. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of?Heart Failure. JACC Heart Fail. 2018 07; 6(7):564-569.
    View in: PubMed
    Score: 0.024
  37. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.024
  38. Heart Rate and Outcomes in Hospitalized?Patients With Heart Failure With Preserved Ejection?Fraction. J Am Coll Cardiol. 2017 Oct 10; 70(15):1861-1871.
    View in: PubMed
    Score: 0.024
  39. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 04 14; 38(15):1132-1143.
    View in: PubMed
    Score: 0.023
  40. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J. 2017 Jun; 188:35-41.
    View in: PubMed
    Score: 0.023
  41. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21; 135(8):724-735.
    View in: PubMed
    Score: 0.022
  42. Influence of Sacubitril/Valsartan (LCZ696)?on?30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016 07 19; 68(3):241-248.
    View in: PubMed
    Score: 0.022
  43. Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
    View in: PubMed
    Score: 0.022
  44. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016 Nov 01; 37(41):3167-3174.
    View in: PubMed
    Score: 0.022
  45. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan; 23(1):20-28.
    View in: PubMed
    Score: 0.022
  46. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.022
  47. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail. 2016 08; 18(8):1021-31.
    View in: PubMed
    Score: 0.021
  48. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 07; 133(23):2254-62.
    View in: PubMed
    Score: 0.021
  49. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Apr; 9(4):e002763.
    View in: PubMed
    Score: 0.021
  50. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.021
  51. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015 Aug; 17(8):809-17.
    View in: PubMed
    Score: 0.020
  52. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14; 36(7):434-9.
    View in: PubMed
    Score: 0.020
  53. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation. 2015 Jan 06; 131(1):43-53.
    View in: PubMed
    Score: 0.019
  54. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014 Nov; 7(6):960-6.
    View in: PubMed
    Score: 0.019
  55. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11):993-1004.
    View in: PubMed
    Score: 0.019
  56. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep; 15(9):1062-73.
    View in: PubMed
    Score: 0.017
  57. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 01; 5(5):571-8.
    View in: PubMed
    Score: 0.017
  58. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 2012 Mar 01; 35(3):233-44.
    View in: PubMed
    Score: 0.016
  59. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep; 4(5):569-77.
    View in: PubMed
    Score: 0.015
  60. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 04; 359(23):2456-67.
    View in: PubMed
    Score: 0.013
  61. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006 Aug 01; 114(5):397-403.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.